A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS5001, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors and Lymphomas
Mechanism of Action
CS5001 is a highly differentiated Antibody Drug Conjugate targeting ROR1. ROR1 is expressed across a variety of cancers, and may play an important role in oncogenesis by activating cell survival signaling events.
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
Location
Similar Trials
Yes
No
Yes
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.